Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study

Trial Profile

Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Amlodipine (Primary) ; HGP 0816 (Primary) ; Losartan (Primary)
  • Indications Dyslipidaemias; Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 14 Nov 2017 Primary endpoint (Change from baseline in sitDBP in the A/L/R 5/100/20 mg and L/R 100/20 mg groups)has been met as per the results published in the Clinical Therapeutics
    • 14 Nov 2017 Primary endpoint (Percentage change from baseline in LDL-cholesterol in the A/L/R 5/100/20 mg group and A/L 5/100 mg group) has been met as per the results published in the Clinical Therapeutics
    • 14 Nov 2017 Results published in the Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top